ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Andrew J. Souers, Joel Johansson, Erwin R. Boghaert, Scott Ackler, Nathaniel D. Catron, Jun Chen, Brian D. Dayton, Hong Ding, Sari H. Enschede, Wayne J. Fairbrother, David C.S. Huang, S.G. Hymowitz, Sha Jin, Seong Lin Khaw, Peter Kovar, Lloyd T. Lam, Jackie Lee, Heather Maecker, Kennan C. Marsh, Kylie D. Mason, Michael J. Mitten, Paul Nimmer, Anatol Oleksijew, Chang H. Park, Cheol‐Min Park, Darren C. Phillips, Andrew W. Roberts, Deepak Sampath, John F. Seymour, Morey L. Smith, Gerard M. Sullivan, Stephen K. Tahir, Chris Tse, Michael Wendt, Xiao Yu, John Xue, Haichao Zhang, Rod Humerickhouse, Saul H. Rosenberg, Steven W. Elmore

Nature Medicine, 2013